Friday, May 10, 2019 Daily Archives

Vibalogics $1.35m expansion feeds ‘booming’ viral vector demand

by

CDMO Vibalogics has increased its single-use bioreactor and purification capacity at its site in northern Germany on the back of growing demand for oncolytic virus and viral vector production. The German contract development and manufacturing organization (CDMO) has added a new manufacturing line consisting of a 50 L and 200 L single-use bioreactors and a Siemens process control system at its site in Cuxhaven. The expansion represents an investment of €1.2 million ($1.35 million), Vibalogics told Bioprocess Insider, and also…

May 10, 2019

Subcutaneous success a boon for Halozyme, but biosimilars hit royalties

by

Roche’s subcutaneous Herceptin (trastuzumab) recently became the third product to be approved using Halozyme Therapeutics’s ENHANZE drug delivery tech. However, Halozyme’s royalties have been hit by biosimilar competition. Halozyme Therapeutics reported what it described as a “strong start to 2019†with revenues of $57 million (€51 million) – up 84% year-on-year – attributed to $30 million upfront license fee from a license agreement struck with argenx in February. That deal gives argenx access to Halozyme’s ENHANZE drug delivery technology to…

May 10, 2019

Bayer plans $150m Californian biologics plant, creating 100 jobs

by

Bayer has teamed with GE Healthcare and Fluor to build a single-use clinical manufacturing plant in Berkeley, California to support its biologics pipeline. Plans have been laid for a 40,000 square-foot ‘Cell Culture Technology Center’ on Bayer’s existing Berkeley campus in California, set to begin production in 2021. The site already makes products including Bayer’s recombinant Factor VIII treatment for hemophilia A. At a cost of $150 million (€134 million), the new plant will “enable clinical and launch production of…

May 10, 2019